London is a globally recognised hub for healthcare innovation, home to specialised investors, clinical partners, and major scaling opportunities. Connecting Scottish healthtech founders with this ecosystem is a vital step for teams looking to raise investment, forge strategic partnerships, and expand their market footprint.
As part of our ongoing work to help Scottish startups build connections beyond Scotland, we’re thrilled to announce the founders joining our upcoming delegation to London.
Meet the cohort
Following an open selection process, five standout companies have been chosen to take part in the core London programme:
Affiniti AI
Represented by co-founder Samuel Stern, Affiniti AI provides therapist-directed CBT support between appointments for people living with depression and anxiety.
XtremeAI
XtremeAI is developing an AI-powered smart pillbox that uses camera and acoustic sensing to identify mixed pills before dispensing. Muhammad Kaleem will represent the company in London.
Danu Insights
CEO and co-founder Stefan Bostock is joining the cohort from Danu Insights, which uses Bayesian experimental design and AI simulations to help organisations run more efficient experiments.
Mayfield Technology
Mayfield Technology’s Log My Health platform turns patient symptom logs into clear summaries for NHS consultations, with co-founders Anna Slodka-Turner and Hanna Cannon both making the trip.
TissueMetrics
Co-founded by Sara Medina-Lombardero and Michael Crichton, TissueMetrics is developing acoustic skin-sensing technology to support more objective assessment and treatment of inflammatory skin conditions.
Showcasing the wider Techscaler ecosystem
Scotland’s life sciences and healthtech community thrives on collaboration, with founders consistently backing one another to succeed on a wider stage.
Alongside our core cohort, five additional high-potential Techscaler member companies have been selected by our Entrepreneurs in Residence to join us in London to expand their networks, meet with investors, and showcase the depth of medtech innovation scaling out of Scotland:
Amytis
Amytis is building a visual workflow and inference platform that connects life-science experiments, data, literature, and AI outputs. CEO and co-founder Eva Steele will represent the team.
Cytochroma
Joined by CEO Kate Laing, Cytochroma creates ethically sourced, diverse stem-cell models to help address gaps in drug development.
Neurobite
CEO Maria Cerezo Sanchez is representing Neurobite, which is developing dissolvable neural interfaces and tailored software to monitor and stimulate brain activity.
Seluna
Seluna uses signal processing and machine learning to speed up the analysis of paediatric sleep studies, with CTO and co-founder Yola Jones attending.
TileBio
Applying AI to digital pathology, TileBio supports advancements in cancer diagnosis, biomarker discovery, and drug development. CEO Christopher Walsh will join the delegation.
We’re looking forward to seeing the partnerships and investor connections these ten companies build during their time in London.
Want to follow their progress and hear about upcoming Techscaler opportunities? Follow us on LinkedIn or sign up for our newsletter.
Programme update: The previously planned Cambridge visit and dinner on 17 November have been cancelled to enable participants to attend the London investor events.
.jpg)
.jpg)
-2.jpg)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
